All neoplasms require angiogenesis and resulting neovascularity for growth beyond 1 mm 2 . Quantitative microvessel density (MVD) has been shown to provide staging and prognostic signi®cance in human prostate cancer (CaP). recently, it has been demonstrated that loss of the wild-type allele of the p53 tumour suppressor gene results in reduced expression of thrombospondin-1 (TSP-1), a potent inhibitor of angiogenesis. There is also an increased expression of vascular endothelial growth factor which promotes neovascularization. p53 gene mutation and MVD were investigated in men with prostate cancer. Sections from 103 radical prostatectomy cases were evaluated with immunohistochemistry to detect mutant p53 proteins. Quantitative MVD was performed on the cases exhibiting p53 positive staining and compared with negative ®elds of similar Gleason grade on the same histologic sections.
Introduction
Adenocarcinoma of the prostate is second only to the nonmelanoma skin cancers as the most common newly diagnosed malignancy in American men; it is also the second greatest cause of cancer-related deaths behind lung cancer. 1 In 1996, there were an estimated 317 100 newly diagnosed cases of prostate cancer and approximately 41 400 deaths. 1 Despite this signi®cance, the rate of clinical diagnosis of prostate cancer is greatly exceeded by the post-mortem prevalence. 2 It has been estimated that 42% of males have identi®able prostate carcinoma at postmortem examination; however, only 9.5% will have a clinical diagnosis of prostate cancer in their lifetime, and only 2.9% will actually die from the disease. 3 The earlier detection of CaP has resulted from the recent trend toward increased screening and the development of more sensitive diagnostic tests. To avoid unnecessary treatment of patients who may have cancer of limited clinical signi®cance, more reliable methods are needed for determining the malignant potential of an individual's cancer.
Angiogenesis is an important factor in the progression and enlargement of solid neoplasms. Stage of breast, 4 bladder, 5 cervix, 6 melanoma, 7±9 lung, 10 and prostate 11±17 carcinomas have all been shown to correlate with the ability of the malignancy to induce an increase in blood supply. The switch to the angiogenic phenotype involves the up-regulation of angiogenic peptides and concomitant down-regulation of inhibitors. Thus, the development of aggressive malignancy may involve genetic changes in¯uencing the expression and activity of angiogenesisrelated molecules. This includes the activation of oncogenes and inactivation of tumour suppressor genes. Mutation of the p53 tumour suppressor gene is the most common genetic alteration in human cancers. 18, 19 The protein product of p53 is a nuclear phosphoprotein that normally facilitates the entrance of cells into the cell cycle and suppresses tumor growth. In its mutant forms, however, it cooperates with cellular oncogenes to transform cells in culture. 20 Inactivation of the wild-type allele, through recombination or errors during mitosis that lead to a loss of the normal chromosome, can thus contribute to tumorigenesis. 21 Although p53 mutations may be infrequent in prostate carcinomas, 22 their occurrence has a negative effect on survival. 23, 24 Several studies have now demonstrated that overexpression of p53 protein, presumably through the process of mutation, de®nes a subset of prostate carcinomas with an adverse clinical outcome.
Neovascularity has been previously investigated as a parameter of prognosis in human prostate cancer. Microvessel density has been shown by our lab 12, 13 and others 16 to be an independent predictor of pathologic stage and may provide useful prognostic information. 25, 26 To date, there have been no studies regarding the relation of angiogenesis to p53 mutation in human prostate cancer. This information may be important in explaining the adverse clinical outcome of men who express p53 abnormality. It also addresses the growing need to discover more accurate preoperative prognostic markers for prostatic malignancies. In this study, we examine a potential relationship between p53 nuclear accumulation and angiogenesis, as measured by microvessel density, in human prostate carcinomas.
Materials and methods
Archival tissue from 103 radical prostatectomy specimens was chosen with a preference for tumours of more advanced pathologic stage. Since p53 nuclear accumulation appears to be associated with advanced stages of disease, this selective measure was utilized to increase the likelihood of identifying more cases with p53 abnormality. The formalin ®xed, paraf®n embedded tissue blocks were cut into ®ve micron sections. Hematoxylin and eosin stained sections were evaluated to select the tissue block that demonstrated the greatest predominance of neoplastic tissue for each case. Serial sections were cut from these blocks.
Immunohistochemistry was employed in the detection of p53 protein with an avidin-biotin complex technique. Sections were deparaf®nized, quenched in 0.3% solution of H 2 O 2 in methanol, and rehydrated. Antigen retrieval was performed with three separate four minute microwave intervals. The sections were incubated in normal goat serum (NGS) to reduce non-speci®c background staining. A positive antibody cocktail and a negative isotypic control were applied to serial sections for overnight incubation at 4 C. We used p53-speci®c antibodies DO-1 (Oncogene Science, Manhasset, NY) at a 1 : 200 (0.5 ug/ml) dilution and DO-7 (Dako, Carpinteria, CA) at a 1 : 3800 (0.025 ug/ml) dilution. The isotypic control for DO-1 was IgG2a (Dako, Carpinteria, CA) at a 1 : 200 (0.5 ug/ml) dilution and for DO-7 was IgG2b (Dako, Carpinteria, CA) at a 1 : 3480 (0.025 ug/ml) dilution. After the sections were washed in phosphate-buffered saline (PBS), they were incubated with biotinylated goat antibodies to mouse IgG (Vector Laboratories, Burlingame, CA) for 1 h. After a PBS wash, ABC complex (ABC Elite, Vector Laboratories, Burlingame, CA) was applied to the sections. The slides were developed using diaminobenzidine (ScyTek Laboratories, Logan, Utah) to produce a brown reaction product and lightly counterstained with hematoxylin.
Adjacent sections to p53 positive slides were further evaluated with factor VIII immunohistochemistry. The sections were digested in 0.1% pronase (Sigma, St. Louis, MO) for 15 min and then covered with 10% NGS blocker for 30 min. Blood vessels were detected by reacting endothelial cells with monoclonal rabbit antibodies to the human von Willebrand factor (Dako, Carpinteria, CA). Antibody was applied to the sections at a dilution of 1 : 1200 and incubated overnight at 4 C. After washing with PBS, the sections were incubated with biotinylated goat antibodies to rabbit IgG (Vector Laboratories, Burlingame, CA) for 30 min at room temperature. Following washing, ABC complex was applied to the sections. The slides were developed using diaminobenzidine with the addition of nickel chloride and H 2 O 2 to produce a black reaction product that illuminated vessels. Methyl green was used for a light counterstain.
Four serial sections were utilized for each case demonstrating p53 immunoreactivity. A hematoxylin & eosin section was necessary to examine the histologic features of the tumour, a p53 section was utilized to ®nd positive p53 nuclei, an isotypic control section was used to ensure that our antibody cocktail was not too sensitive, and a factor VIII section was used to perform the actual MVD quanti®cation. Staining was de®ned as positive for p53 whenever any clear nuclear immunoreactivity was detected.
The factor VIII ®elds that corresponded to the p53 positive epicenters and their controls were quanti®ed for MVD with an image analysis protocol de®ned here and in previous publications. 12, 13, 15 Sections were ®rst evaluated with a compound microscope (Nikon, Garden City, NY). A black and white analog charge-coupled device video camera (Dage-MTI, Michigan City, IN) coupled to an internal frame-grabbing board (PIP640, Matrox Electronic Systems Ltd., Dorval, Quebec, Canada) was used to capture and digitize each desired ®eld. A high resolution RGB monitor (Sony Corp. of America, Park Ridge, NJ) displayed the image. The image was quanti®ed on a 486-50 computer (Compaq Computer Inc. Houston, TX) with the Optimas image analysis software package (Bioscan Inc., Edmonds, WA).
We quanti®ed vessel density with 0.25 mm 2 ®elds surrounding each epicenter of p53 nuclear accumulation. For each positive staining foci, three p53 negative ®elds of similar Gleason grade were selected and quanti®ed on the same histologic section to serve as controls. Vessels, stained black, were discriminated from the lightly stained methyl green background by a manually set threshold level on the computer. A retouching facility was used by the operator to illuminate small capillaries not automatically detected by the initial threshold setting and to eliminate objects determined not to be vessels. All illuminated objects in the selected ®eld were then counted, and data was collected and stored with Microsoft Excel (Microsoft Corporation, Redmond, WA). MVD data were then converted to vessels per mm 2 for subsequent analysis. Final statistical analysis was performed with Stat-View (Abacus Concepts, Inc., Berkeley, CA) and with JMP (SAS Institute Inc., Cary, NC). . This data showed statistically signi®-cant differences in MVD between positive ®elds and controls with P`0.0001 (Table 1, Figure 2 ). areas (Figure 3) . The control ®elds were all p53 negative, with no immunoreactive nuclei, and they revealed a very different situation (Figure 4) . Unlike the p53 positive ®elds, there was very little vascularity, and most of the vessels could only be found in the stroma at the periphery of the tumour. These control ®elds appeared to have very little angiogenic induction within the center of the neoplastic tissue.
Results

Of
It is also worth noting that of the seven cases which were not statistically signi®cant, six demonstrated higher MVD in the p53 positive areas and one showed virtually no difference.
Discussion
Our histological analysis was made possible with the use of antibodies directed at p53 proteins. Due to its short half-life, the wild-type protein is generally undetectable by immunohistochemistry. In contrast, studies directly sequencing the p53 gene have shown that mutated p53 proteins are readily detectable with immunohistochemistry. 27, 28 The antibodies used in our study were directed against epitopes present in the wild-type and several forms of the mutant protein product. Since the wildtype protein is labile and its nuclear concentration is believed to be below the limits of immunohistochemical detection, any detection of p53 protein immunoreactivity can be considered indirect evidence of p53 gene mutation. This assumption is supported by studies performed by Oren and Bruner et al. 19Y29 The nuclear accumulation of p53 protein is a potential factor involved in angiogenesis and may serve as an effective prognostic measure for human prostate cancer. In a study by Visakorpi et al, 23 a high level of p53 accumulation was associated with high histologic grade, DNA aneuploidy, and a high cell proliferation rate. High-level p53 immunostaining provided one of the best predictors of progression in prostate carcinoma and was associated with a 12-fold increase in mortality. Gasparini and colleagues 30 found that in node-negative breast carcinoma, patients with the poorest prognosis had the most highly vascularized and p53 positive tumours, whereas the least vascularized and p53 negative groups had the best outcome.
A potential relationship between p53 gene mutation and angiogenesis has recently been reported by Dameron et al. 31 These investigators studied ®broblasts cultured from patients with Li-Fraumeni syndrome. These patients have inherited one wild-type and one mutant allele of the p53 gene, thus increasing their risk of developing sarcomas and other tumours after the remaining wild-type allele is inactivated. 32, 33 Upon continued passage in culture, the diploid ®broblasts spontaneously lose their wildtype allele and become aneuploid and immortal, retaining only the mutant allele of p53. 34, 35 These investigators further demonstrated that the switch to the angiogenic phenotype coincides with loss of the wild-type p53 allele. This leads to decreased expression of thrombospondin-1 (TSP-1), a potent inhibitor of angiogenesis. Using a transfection assay, it was shown that the p53 gene can stimulate endogenous TSP-1 and positively regulate TSP-1 promoter sequences.
Further evidence also supports a relationship between the p53 gene and neovascularization. Erwin and colleagues 36 reported the release of an angiogenic inhibitor upon induction of wild type p53 expression in glioblastoma cells. Studies by Kieser and colleagues 37 suggest that mutant p53 cells in vitro result in increased expression of vascular endothelial growth factor, a pivotal mediator of tumour angiogenesis. Furthermore, Gasparini and colleagues 38 have demonstrated a signi®cant correlation, in clinical specimens of head and neck tumours, between quanti®ed neovascularization and the presence of p53 overexpression; the latter was determined to be a signi®-cant predictor of the development of metastases.
Conclusions
These recent conclusions encouraged us to study p53 gene mutation and its impact on microcirculation in prostate cancer. In this initial study, we have demonstrated the differences with regard to microvessel density between carcinoma exhibiting the p53 wild-type and carcinoma with p53 mutation. This positive correlation between p53 gene mutation and angiogenesis may be a partial explanation of the general worse prognosis in men with p53 abnormality. This research will help further our understanding of the relationship between these two potential markers. Future research to determine the precise biologic mechanism relating p53 mutation and MVD will help to establish their prognostic signi®cance. This is important as increased public awareness and sensitive detection methods are resulting in the earlier diagnosis of smaller prostatic neoplasms with unknown malignant potential.
